Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-Kras(G12D/+);Tp53(R172H/+) (KPC) mice, a genetically engineered model of pancreatic cancer

PurposeMetarrestin is a first-in-class small molecule clinical candidate capable of disrupting the perinucleolar compartment, a subnuclear structure unique to metastatic cancer cells. This study aims to define the pharmacokinetic (PK) profile of metarrestin and the pharmacokinetic/pharmacodynamic relationship of metarrestin-regulated markers.MethodsPK studies included the administration of single or multiple dose of metarrestin at 3, 10, or 25mg/kg via intravenous (IV) injection, gavage (PO) or with chow to wild-type C57BL/6 mice and KPC mice bearing autochthonous pancreatic tumors. Metarrestin concentrations were analyzed by UPLC-MS/MS. Pharmacodynamic assays included mRNA expression profiling by RNA-seq and qRT-PCR for KPC mice.ResultsMetarrestin had a moderate plasma clearance of 48mL/min/kg and a large volume of distribution of 17L/kg at 3mg/kg IV in C57BL/6 mice. The oral bioavailability after single-dose (SD) treatment was >80%. In KPC mice treated with SD 25mg/kg PO, plasma AUC(0-) of 14400ngh/mL, C-max of 810ng/mL and half-life (t(1/2)) of 8.5h were observed. At 24h after SD of 25mg/kg PO, the intratumor concentration of metarrestin was high with a mean value of 6.2 mu g/g tissue (or 13 mu M), well above the cell-based IC50 of 0.4 mu M. At multiple dose (MD) 25mg/kg/day PO in KPC mice, mean tissue/plasma AUC(0-24h) ratio for tumor, spleen and liver was 37, 30 and 31, respectively. There was a good linear relationship of dosage to AUC(0-24h) and C-24h. AUC(0-24h) MD to AUC(0-24h) SD ratios ranged from two for liver to five for tumor indicating additional accumulation in tumors. Dose-dependent normalization of FOXA1 and FOXO6 mRNA expression was observed in KPC tumors.ConclusionsMetarrestin is an effective therapeutic candidate with a favorable PK profile achieving excellent intratumor tissue levels in a disease with known poor drug delivery.

See More